other material
confidence high
sentiment positive
materiality 0.85
Arcus ARC-7 Phase 2: domvanalimab doublet cuts progression risk 45% vs. zimberelimab
Arcus Biosciences, Inc.
- Median PFS: doublet 12.0 mo, triplet 10.9 mo vs. monotherapy 5.4 mo (HR 0.55 and 0.65).
- Confirmed ORR: doublet 41%, triplet 40% vs. monotherapy 27% in PD-L1≥50% 1L NSCLC.
- Six-month PFS rate: doublet 65%, triplet 63% vs. monotherapy 43%; median follow-up ~12 mo.
- No new safety signals; Grade≥3 AEs: doublet 47%, triplet 52% vs. monotherapy 58%.
- Trial continues to monitor overall survival; data cutoff Aug 31, 2022 (n=149 safety, 133 efficacy).